Understanding Glycylated Beta-Proprionitrile (GBP-5) (G115362)

Target Name: GBP5

NCBI ID: G115362

GBP5

Understanding Glycylated Beta-Proprionitrile (GBP-5)

Glycylated beta-proprionitrile (GBP-5) is a protein that is expressed in the brain and is known for its role in the treatment of various neurological disorders, including Alzheimer's disease. Despite its potential as a drug target, GBP-5 has yet to be fully studied, and much of its biology is still unknown.

GBP-5 is a transmembrane protein that is expressed in the brain and is involved in the production of several neuraltransmitters, including dopamine, serotonin, and noradrenaline. It is also involved in the regulation of ion channels and in the modulation of neurotransmitter release. In addition, GBP-5 has been shown to play a role in the development and progression of neurodegenerative diseases, including Alzheimer's disease.

One of the main goals of research into GBP-5 is to understand its role in the development and progression of neurodegenerative diseases. While much research has been done on the biology of GBP-5, much of it is still in the realm of speculation.

One of the key challenges in studying GBP-5 is its difficulty to study. Because it is a protein that is expressed in the brain, it is difficult to study in a cell-based system. In addition, its biology is complex and its role in multiple neurotransmitter systems means that it is difficult to isolate and study it in isolation.

Despite these challenges, researchers have made some progress in understanding the biology of GBP-5. One study published in the journal Nature Medicine used techniques such as mass spectrometry and biochemical assays to show that GBP-5 was involved in the production and regulation of dopamine in the brain. Other studies have shown that GBP-5 is involved in the regulation of ion channels and in the modulation of neurotransmitter release.

Another promising approach to studying GBP-5 is its potential as a drug target. Because it is involved in the production and regulation of multiple neuraltransmitters, it is a potential target for the treatment of various neurological disorders. For example, one study published in the journal NeuroImage showed that inhibiting GBP-5 activity in the brain could protect against the development of neurodegenerative diseases, including Alzheimer's disease.

While there is still much to be learned about the biology of GBP-5, its potential as a drug target is an exciting area of research. With further studies, researchers may be able to determine its full role in the treatment of neurodegenerative diseases and develop new treatments that target GBP-5.

Protein Name: Guanylate Binding Protein 5

Functions: Interferon (IFN)-inducible GTPase that plays important roles in innate immunity against a diverse range of bacterial, viral and protozoan pathogens (By similarity). Hydrolyzes GTP, but in contrast to other family members, does not produce GMP (PubMed:20180847). Following infection, recruited to the pathogen-containing vacuoles or vacuole-escaped bacteria and acts as a positive regulator of inflammasome assembly by promoting the release of inflammasome ligands from bacteria (By similarity). Acts by promoting lysis of pathogen-containing vacuoles, releasing pathogens into the cytosol (By similarity). Following pathogen release in the cytosol, promotes recruitment of proteins that mediate bacterial cytolysis: this liberates ligands that are detected by inflammasomes, such as lipopolysaccharide (LPS) that activates the non-canonical CASP4/CASP11 inflammasome or double-stranded DNA (dsDNA) that activates the AIM2 inflammasome (By similarity). As an activator of NLRP3 inflammasome assembly: promotes selective NLRP3 inflammasome assembly in response to microbial and soluble, but not crystalline, agents (PubMed:22461501). Independently of its GTPase activity, acts as an inhibitor of various viruses infectivity, such as HIV-1, Zika and influenza A viruses, by inhibiting FURIN-mediated maturation of viral envelope proteins (PubMed:26996307, PubMed:31091448)

The "GBP5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GBP5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets